Aap Implantate Ag · XETR:AAQ1
Aap Implantate — Non-Deal Roadshow (August 2015)
21 slides from Aap Implantate's roadshow presentation, Aug 18, 2015
Slide 1: aap Implantate AG Corporate Presentation Roadshow London 2015
aap Implantate AG Corporate Presentation Roadshow London 2015 London, August 18 - 19, 2015 Bruke Seyoum Alemu, CEO Marek Hahn, CFO
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: aap Overview
aap Overview • German based international MedTech company Sales 2014*: • Focus on trauma and biomaterials EUR 30.6 million • Core technology in trauma is LOQTEQ®: Sales of EUR 8.2 million (+63%) in 2014 Projects Other 3% 4% • Core technology in biomaterials is PMMA bone cements/ accessories: Trauma
Slide 4: aap's Centers of Excellence
aap‘s Centers of Excellence Innovations in Trauma and Biomaterials Center of Excellence for Trauma Center of Excellence for Biomaterials Berlin Dieburg • Products and Services • Products and Services: – Comprehensive plates & screws portfolio – Comprehensive portfolio of bone cements and – R&D and m
Slide 5: Core technology of Trauma – LOQTEQ®
Core technology of Trauma – LOQTEQ® The Concept The Applications The Competitive Environment Synthes Stryker Zimmer S&N Königsee aap 5
Slide 6: Core technology of Trauma – LOQTEQ®
Core technology of Trauma – LOQTEQ® The Portfolio The Growth LOQTEQ® sales in EUR million 9 8 7 6 5 4 8.2 3 5.0 2 1 0.4 1.8 0 2011 2012 2013 2014 The Value • Patented locking compression technology • Genuine alternative to the gold standard with new and additional features • Clinical and economical
Slide 7: LOQTEQ® – portfolio extension
LOQTEQ® – portfolio extension Beyond Phase Value added 2012 2013 2014 2015 2016 2017 Proximal Humerus One Step, One Hole, One I Distal Femur Screw ✓ Proximal Tibia Flexible compression Distal Tibia Clavicle One Step, One Hole, One Osteotomy II Elbow Screw, Flexible ✓ compression Tibia III Periprosth
Slide 8: aap Biomaterials
aap Biomaterials Technologies & Products Bone cements Comprehensive portfolio • Arthroplasty Bone Cements • Augmentation Bone Cements Platform technologies • HA-PMMA Bone Cements State-of-art products • Silver Bone Cement Innovative pipeline Accessories for bone cement application • Disposable vacuu
Slide 9: aap Biomaterials – Propositions in cement business
aap Biomaterials Propositions in cement business Strategic supplier to its global OEM customers Strategic positioning Customers Focused and reputable cement competency 9 of the top-10 orthopedic OEM manufacturers Cost-effective service for the OEM cement market Strong reputation and highest customer
Slide 10: Silver Coating
Silver Coating Value-based innovation The Unmet Need The Solution Surgical Site Infection (SSI) ✓ Cost-effective coating technique ✓ Applicable on any type of geometry Biofilm formed on an TiAl6V4 ✓ Very high efficacy (in vitro / in vivo) implant surface S. epidermidis ATCC 35984 ✓ Very good biocomp
Slide 11: Global Trauma Market
Global Trauma Market Key dynamics, trends and valuation Development Global Market EV/ Date Buyer Target firm Transaction – Trauma is fastest growing segment in Orthopedics Sales • Orthopedics: total: $6 billion revenue, 3% growth Small Bone 2014 Stryker Innovations 5.94 M&A • Relevant Trauma segment
Slide 12: aap – 2015 and beyond
aap – 2015 and beyond DIFFERENTIATION GROWTH VALUE CREATION aap with a unique position aap with multiple drivers for aap with a sound strategy to and opportunity for future delivering profitable growth create value growth Focused on most attractive, Continuous new product Profitable growth 2-3 times
Slide 13: aap's Aspiration and Imperatives
aap’s Aspiration and Imperatives MISSION Making trauma treatment better and cost-effective VISION Become a leading European trauma company STRATEGIC IMPERATIVES Products Customers Distribution Services Accelerating value-based Enhancing market access innovation Getting focused on Trauma Geography Op
Slide 14: Management Agenda 2015
Management Agenda 2015 Products Customers Accelerating Value-based Innovation Enhancing Market Access • LOQTEQ® portfolio expansion targeting indication • Trauma sales growth: 20% to 25% (2-3x faster coverage >90% than the trauma market) Distribution • Silver technology: Submission for CE approval i
Slide 15: Highlights FY/2014 and H1/2015
Highlights FY/2014 and H1/2015 Strategic Imperatives Products Customers Accelerating Value-based Innovation Enhancing Market Access • LOQTEQ®: Continuous portfolio expansion; • Continuous Trauma and LOQTEQ® sales growth European & US patents obtained • USA: Conclusion of eight LOQTEQ® distribution D
Slide 16: Highlights H1/2015 – Financial Figures
Highlights H1/2015 – Financial Figures (in EUR million) H1/2015* H1/2014 Change Sales 13.6 14.2 -4% Trauma 5.6 5.1 11% of which LOQTEQ® 3.7 2.9 27% Biomaterials 7.6 8.4 -9% Projects 0.2 0.2 10% Other 0.2 0.5 -72% H1/2015* H1/2014 Change EBITDA -0.6 1.6 < -100% of which projects 0.2 0.0 > +100% of wh
Slide 17: Highlights FY/2014 – Financial Figures
Highlights FY/2014 – Financial Figures (in EUR million) FY/2014* FY/2013 Change Sales 30.6 28.6 7% Trauma 12.2 9.6 27% of which LOQTEQ® 8.2 5.0 63% Biomaterials 16.4 15.0 10% Projects 1.2 2.8 -58% Other 0.8 1.2 -31% FY/2014* FY/2013 Change EBITDA 2.3 5.1 -55% of which projects 0.8 4.4 -82% of which
Slide 18: Shareholder structure
Shareholder structure • Growing interest in aap´s value driving strategy is also reflected in new shareholders: – December 2013: Taaleritehdas ArvoRein Equity Fund, Finland – March 2014: Ennismore Fund Management Limited, UK – April 2014: Fidelity Funds SICAV, Luxembourg – January 2015: Ratio Capita
Slide 19: Financial Outlook 2015
Financial Outlook 2015 • Sales: EUR 33 million – EUR 35 million (+8% to +14%; FY/2014: EUR 30.6 million) Trauma: EUR 14.8 million – EUR 15.4 million (+20% to +25%; FY/2014: EUR 12.2 million) Biomaterials: 10% growth • EBITDA: EUR 2.5 million – EUR 3.5 million (+9% to +52%; FY/2014: EUR 2.3 milli
Slide 20: Notes
Notes 20
Slide 21: Contact
Contact aap Implantate AG Lorenzweg 5 12099 Berlin Fabian Franke Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de Website: www.aap.de IR-app: 21